Yuanjun Jiang

1.0k total citations
47 papers, 734 citations indexed

About

Yuanjun Jiang is a scholar working on Molecular Biology, Surgery and Cancer Research. According to data from OpenAlex, Yuanjun Jiang has authored 47 papers receiving a total of 734 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 11 papers in Surgery and 11 papers in Cancer Research. Recurrent topics in Yuanjun Jiang's work include Bladder and Urothelial Cancer Treatments (7 papers), Ferroptosis and cancer prognosis (6 papers) and Cancer-related molecular mechanisms research (6 papers). Yuanjun Jiang is often cited by papers focused on Bladder and Urothelial Cancer Treatments (7 papers), Ferroptosis and cancer prognosis (6 papers) and Cancer-related molecular mechanisms research (6 papers). Yuanjun Jiang collaborates with scholars based in China, Japan and Mexico. Yuanjun Jiang's co-authors include Qiao Qiao, Guang Li, Chuize Kong, Chiyuan Piao, Xiaojun Man, Xiaolu Cui, Xuyong Lin, Ning Han, Guangqi Li and Miao Zhang and has published in prestigious journals such as PLoS ONE, Cell stem cell and The Journal of Urology.

In The Last Decade

Yuanjun Jiang

45 papers receiving 726 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yuanjun Jiang China 18 365 175 117 115 111 47 734
Fu-Ju Chou United States 17 356 1.0× 233 1.3× 116 1.0× 73 0.6× 228 2.1× 22 682
Hubin Yin China 18 613 1.7× 377 2.2× 101 0.9× 91 0.8× 155 1.4× 29 886
Ren Zhao China 15 721 2.0× 279 1.6× 212 1.8× 89 0.8× 191 1.7× 36 993
Kuo Yang China 19 497 1.4× 263 1.5× 152 1.3× 47 0.4× 219 2.0× 52 825
Sylvie Shen Australia 14 447 1.2× 177 1.0× 202 1.7× 123 1.1× 171 1.5× 26 840
Shinji Kitamura Japan 12 606 1.7× 156 0.9× 95 0.8× 40 0.3× 103 0.9× 17 801
Fenghua Guo China 14 367 1.0× 248 1.4× 104 0.9× 125 1.1× 63 0.6× 31 667
William Tse United States 17 419 1.1× 116 0.7× 159 1.4× 109 0.9× 124 1.1× 50 905
Shi Zuo China 14 484 1.3× 221 1.3× 142 1.2× 54 0.5× 98 0.9× 52 837

Countries citing papers authored by Yuanjun Jiang

Since Specialization
Citations

This map shows the geographic impact of Yuanjun Jiang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuanjun Jiang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuanjun Jiang more than expected).

Fields of papers citing papers by Yuanjun Jiang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuanjun Jiang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuanjun Jiang. The network helps show where Yuanjun Jiang may publish in the future.

Co-authorship network of co-authors of Yuanjun Jiang

This figure shows the co-authorship network connecting the top 25 collaborators of Yuanjun Jiang. A scholar is included among the top collaborators of Yuanjun Jiang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuanjun Jiang. Yuanjun Jiang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhang, Hao, et al.. (2025). Methyltransferase-like 7B participates in bladder cancer via ACSL3 m6A modification in a ferroptosis manner. Biology Direct. 20(1). 9–9. 3 indexed citations
2.
Jiang, Yuanjun, Jing Li, Linlin Mao, et al.. (2024). Osteocytes/Osteoblasts Produce SAA3 to Regulate Hepatic Metabolism of Cholesterol. Advanced Science. 11(24). e2307818–e2307818. 5 indexed citations
3.
4.
Wei, Xiaocui, Tiantian Wei, Zhijie Lin, et al.. (2024). A human organoid drug screen identifies α2-adrenergic receptor signaling as a therapeutic target for cartilage regeneration. Cell stem cell. 31(12). 1813–1830.e8. 23 indexed citations
5.
Jiang, Yuanjun, Linlin Mao, Sheng Zhang, et al.. (2023). Exosome Release Delays Senescence by Disposing of Obsolete Biomolecules. Advanced Science. 10(8). e2204826–e2204826. 26 indexed citations
6.
Jiang, Yuanjun, Zheng Zhou, Shanshan Zhu, et al.. (2022). Prediction of the postoperative prognosis in patients with non-muscle-invasive bladder cancer based on preoperative serum surface-enhanced Raman spectroscopy. Biomedical Optics Express. 13(8). 4204–4204. 9 indexed citations
7.
Zhang, Hao, et al.. (2022). The oncogenic role of TFAP2A in bladder urothelial carcinoma via a novel long noncoding RNA TPRG1-AS1/DNMT3A/CRTAC1 axis. Cellular Signalling. 102. 110527–110527. 12 indexed citations
8.
9.
Liu, Xi, Shuangjie Liu, Chiyuan Piao, et al.. (2021). Non‐metabolic function of MTHFD2 activates CDK2 in bladder cancer. Cancer Science. 112(12). 4909–4919. 23 indexed citations
10.
Li, Guangqi, et al.. (2021). Comprehensive analysis of radiosensitivity in head and neck squamous cell carcinoma. Radiotherapy and Oncology. 159. 126–135. 19 indexed citations
11.
Man, Xiaojun, Chiyuan Piao, Xuyong Lin, et al.. (2019). USP13 functions as a tumor suppressor by blocking the NF-kB-mediated PTEN downregulation in human bladder cancer. Journal of Experimental & Clinical Cancer Research. 38(1). 259–259. 72 indexed citations
12.
13.
Sun, Chaonan, et al.. (2017). Inhibition of GRP78 abrogates radioresistance in oropharyngeal carcinoma cells after EGFR inhibition by cetuximab. PLoS ONE. 12(12). e0188932–e0188932. 20 indexed citations
14.
Qiao, Ying, et al.. (2015). Decreased TIM-3 mRNA expression in peripheral blood mononuclear cells from nephropathy patients. Genetics and Molecular Research. 14(2). 6543–6548. 5 indexed citations
15.
Jiang, Yuanjun, et al.. (2015). Rab23 is overexpressed in human bladder cancer and promotes cancer cell proliferation and invasion. Tumor Biology. 37(6). 8131–8138. 36 indexed citations
16.
Qiao, Qiao, Yuanjun Jiang, & Guang Li. (2013). Inhibition of the PI3K/AKT-NF-κB Pathway With Curcumin Enhanced Radiation-Induced Apoptosis in Human Burkitt’s Lymphoma. Journal of Pharmacological Sciences. 121(4). 247–256. 83 indexed citations
17.
Qiao, Qiao, et al.. (2012). Curcumin improves the antitumor effect of X-ray irradiation by blocking the NF-κB pathway. Anti-Cancer Drugs. 23(6). 597–605. 31 indexed citations
18.
19.
Liu, Haibo, Chuize Kong, Yu Zeng, et al.. (2008). Livin may serve as a marker for prognosis of bladder cancer relapse and a target of bladder cancer treatment. Urologic Oncology Seminars and Original Investigations. 27(3). 277–283. 16 indexed citations
20.
Jiang, Yuanjun. (2006). Clinical analysis of malignant pheochromocytoma. Zhongguo xiandai yixue/Zhongguo xiandai yixue zazhi. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fu-Ju Chou Breakdown of academic impact, for papers by Hubin Yin Breakdown of academic impact, for papers by Ren Zhao Breakdown of academic impact, for papers by Kuo Yang Breakdown of academic impact, for papers by Sylvie Shen Breakdown of academic impact, for papers by Shinji Kitamura Breakdown of academic impact, for papers by Fenghua Guo Breakdown of academic impact, for papers by William Tse Breakdown of academic impact, for papers by Shi Zuo
Rankless by CCL
2026